Check out our most popular compounded medications! Get Started
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Prepared to a prescriber's order for one patient. Not FDA-approved.
Clindamycin is a lincosamide antibiotic, commonly compounded into topical gels, solutions, lotions and foams, oral liquids and combination acne preparations.
Clindamycin is a lincosamide antibiotic. It binds the 50S subunit of the bacterial ribosome and blocks protein production, which stops susceptible bacteria from growing; in acne it is active in the laboratory against Cutibacterium acnes, and a 2024 review describes its antibacterial and anti-inflammatory properties as thought to act together, although the gel label calls the mechanism in acne unknown. Manufactured products include Cleocin HCl capsules, FDA-approved for serious infections caused by susceptible anaerobes, streptococci, pneumococci and staphylococci, reserved for people who cannot take penicillin; clindamycin phosphate 1% topical gel, approved for acne vulgaris; and Cleocin 2% vaginal cream, approved for bacterial vaginosis. Fixed combinations with benzoyl peroxide, tretinoin or adapalene are also manufactured. A prescriber might order clindamycin compounded when a patient needs a topical strength or vehicle that is not manufactured, an alcohol-free or allergen-free base, a flavored oral liquid, or a combination with another active ingredient in one preparation. Compounded preparations are not FDA-approved and require a prescription.
Oral clindamycin carries an FDA boxed warning for Clostridioides difficile infection, which ranges from mild diarrhea to fatal colitis and has been reported more than two months after treatment; because of this risk the label reserves it for serious infections where less toxic antibiotics are not appropriate. Topical and vaginal clindamycin are absorbed in small amounts and colitis has been reported with them too, so call your prescriber for watery or bloody diarrhea or stomach cramps, and avoid anti-diarrheal medicines unless advised. Do not use clindamycin if you are allergic to clindamycin or lincomycin; topical and vaginal products are also not for people with a history of regional enteritis, ulcerative colitis or antibiotic-associated colitis. Clindamycin can strengthen neuromuscular blocking drugs, and CYP3A4 inhibitors or inducers change its levels. The vaginal cream can weaken condoms and diaphragms for 72 hours. Use after the first trimester has not been linked to birth defects; LactMed says breastfeeding need not stop, with infants watched for diarrhea or thrush. Topical side effects include dryness, burning, itching and redness. Talk to your prescriber or pharmacist about any side effect that concerns you.
Clindamycin binds 23S rRNA in the peptidyl transferase center of the 50S ribosomal subunit, inhibiting peptide bond formation; it is bacteriostatic. Oral absorption is about 90% and unaffected by food, average half-life is 2.4 hours, and metabolism is hepatic via CYP3A4 with minor CYP3A5 contribution, yielding clindamycin sulfoxide; CSF penetration is inadequate for meningitis. Topical clindamycin phosphate is an inactive prodrug hydrolyzed in vivo to active drug; after repeated application serum levels are very low, though enough can be absorbed to produce systemic effects. Vaginal absorption averages about 5%. Labeled indications: Cleocin HCl for serious anaerobic, streptococcal, pneumococcal and staphylococcal infections in penicillin-inappropriate patients; clindamycin phosphate 1% gel for acne vulgaris; Cleocin vaginal cream 2% for bacterial vaginosis including second and third trimester pregnancy. Beyond the label, the Armillei 2024 review describes clindamycin for superficial bacterial folliculitis, folliculitis decalvans with rifampin, mild rosacea and hidradenitis suppurativa, and S. aureus skin and soft tissue infection, and advises against topical clindamycin monotherapy because of resistance; MedlinePlus lists anthrax, malaria, toxoplasmosis and endocarditis prophylaxis. Dosing is per prescriber. Monitor for diarrhea and CDI, hypersensitivity, and with prolonged systemic therapy, liver and kidney function and blood counts. Clindamycin is not a controlled substance.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
